Follicular development pathway

Follicular development pathways encompass the highly regulated biological processes through which primordial follicles progress to the preovulatory stage within the ovary [1]. This progression is governed by a complex interplay of endocrine signals, primarily follicle-stimulating hormone (FSH) and luteinizing hormone (LH), alongside paracrine and autocrine factors such as growth differentiation factor 9 (GDF9) and bone morphogenetic proteins (BMPs) [2]. These pathways are essential for female fertility, as they ensure the maturation of a competent oocyte and the production of steroid hormones like estrogen and progesterone [1]. The process involves distinct stages, including the gonadotropin-independent primordial-to-primary transition and the gonadotropin-dependent antral stage [2]. Dysregulation of these pathways is central to various reproductive disorders, including polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) [3]. Therapeutic strategies often target specific components of these pathways, such as the FSH receptor or aromatase enzyme, to manage infertility or control ovulation during assisted reproductive technologies [1]. Drugs like follitropin and clomiphene are commonly used to modulate these pathways to induce ovulation [1]. Understanding these pathways is also critical in the context of ovarian cancer research and the development of contraceptives [2].

Other names

Ovarian folliculogenesisFollicle maturationOvarian follicle development

Pharmacological intervention typically involves the modulation of specific receptors (e.g., FSHR, LHCGR) or enzymes (e.g., Aromatase) within the pathway to stimulate or inhibit follicle maturation and ovulation.